The first dose of AstraZeneca Covid-19 vaccine was related to a “very small” increased risk of bleeding and other rare blood disorders, as per researchers.
The research findings were published in the Nature Medicine Magazine on Wednesday stopped from a study in Scotland, which involved around 2.53 million people who received their first doses of COVID-19 vaccines between December 8 to April 14, comprising 57.5% of the country’s adult population.Out of the total, some 1.7 million people have received the AstraZeneca vaccine, and about 820,000 people were to receive Pfizer’s vaccine.
While the COVID-19 vaccine is not yet approved for use in the United States, an independent committee advising vaccinations in the United Kingdom previously suggested it to those aged 18-39 with no underlying health issues have been provided by a substitute to the shot. As of April 21, the United Kingdom regulatory body (MHRA) received 209 reports of lower platelet levels against a backdrop of 22 million first doses.Researchers informed an increased risk of extremely low platelet count within six days of vaccination with the AstraZeneca vaccine.
Study authors have reported 22 patients with irregular drop in platelet count, though nearly half of them already had prior prescriptions that could bring up the issue. The study suggests that very few ITP patients were given ITP therapies after receiving vaccine.Scholars also observed three deaths post ITP, though they were not due to ITP, and the deaths had occurred in both vaccinated and unvaccinated people over the age of 70.